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ABSTRACT

A method of supplementing a diet and ameliorating oxidative
stress in a mammal includes administering a pharmaceuti

cally effective amount of lipid soluble, hydrophobic active
compounds having a chemical structure:
R1
/\
R2 R2
wherein R1 is an aromatic backbone and R2 is a sulfur

containing ligand. Through formation of disul?de link
ages other moieties can be attached to R2 converting the
hydrophobic base into a water soluble entity, for ease of
delivery, which can be reconverted back to the original

compound by biochemical reduction in the blood
stream.

45 Claims, No Drawings
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METHOD OF AMELIORATING OXIDATIVE
STRESS AND SUPPLEMENTING THE DIET

from GSSG, (3) decrease free radical formation by reversing
heavy metal inhibition of the mitochondrial electron transport

This application is a continuation-in-part (CIP) of US.
patent application Ser. No. 12/731,415 ?led on 25 Mar. 2010,
the full disclosure of Which is incorporated herein by refer

oxidation of naturally produced GSH to GSSG. With these
four properties such a compound could dramatically increase
intracellular GSH and reduce free radical damage and alloW

system, and (4) scavenge hydroxyl free radicals preventing
m

the cells to recover to a normal state. In addition, the increase

ence.

in intracellular GSH Would alloW GST to remove organic
TECHNICAL FIELD

toxins built up during periods of toxicity and enhance the
ability of the P-450 system to further detoxify the subject
using the natural system. For example, it is Well knoWn that
GSH is directly involved in binding to components of viral
replication systems inhibiting viral replication. LoW GSH

The present invention relates generally to the ?eld of
dietary supplements for mammals and, more particularly, to
methods of supplementing a diet, removing heavy metals and
other toxins and ameliorating oxidative stress.

levels are a major risk factor for several viral infections and

BACKGROUND OF THE INVENTION

high GSH seems involved in reversing and preventing such

Heavy metals such as mercury, lead, cadmium and silver
can bind to proteins on the proteins’ incorporated cysteine

viral infections.
In order to medically prevent or reduce the oxidative stress
problem identi?ed as loW GSH levels, heavy metals must be

residues Which contain sulfhydryl or iSH groups. This

abnormally inhibits or activates their biological properties.
Further, a heavy metal binding speci?c proteins can induce
damage that leads to overproduction or leakage of reactive
oxygen species (ROSs) from their normal locations. These
ROSs, mostly produced in the mitochondria of the cells of the
body, then react With protein, nucleic acid (DNA, RNA) and

20

excreted by natural means or complexed by medically based
chelator compounds that render them biologically unavail
able to elicit their toxic effects. To effect this removal and

tightly bind the heavy metals, the treating compound must be
25

able to effectively remove the metal from the single sulfur
residue and bind it more tightly than is capable With only one
sulfur to metal bond. That is, the compound must make at

lipid molecules in the healthy cell changing their property/

least tWo intramolecular sulfur to metal bonds to be able to

chemistry and leading to unhealthy cells that may die or at

prevent subsequent reaction or exchange of the complexed

least be unable to defend themselves from other stress factors
such as viral infection. In addition to heavy metals there are
many other chemical toxicants that can induce oxidative

metal With other biomolecules. This requires that the chelat

stress including, for example, radiation toxicity, acetomi

ing molecule contain at least tWo sulfhydryls that are one
extended arms that alloW for extended freedom of rotation
and movement of the sulfhydryls so that the most stable

nophen and dioxin. Further, it is Well knoWn that the oxidation

orientiation for binding the heavy metal can be obtained. For

30

example, the ideal chelating compound must have degrees of

of reduced glutathione (GSH) to oxidiZed glutathione (G-Si
S-G) is one of the ?rst biochemical signals for apoptotic cell

death (or programmed cell death). The inadvertent oxidation

freedom of rotation and movement of the sulfur bonds to be
able to bind different heavy metals that have different coor

of GSH by toxin produced ROSs could lead to increased
GSSG and cell death also. In the healthy body GSH accom

dination chemistries (e.g. different bond angles that confer
tighter bonding). For example, Hg2+ and Pb2+ both can form

35

plishes protection against heavy metal toxicity, organic toxins
and hydroxyl free radical damage due to its chemical ability
to; (l) chelate heavy metals, (2) its use by the enZyme glu
tathione-S-transferase (GST) to produce GS-toxin complexes

tWo bonds With iSH groups, but the most stable binding of
40

toxicity and radiation toxicity as Well as oxidative stress asso

that are actively removed from the intracellular location into

the blood and then actively removed from the blood by GS
toxin receptors in the bilary transport system of the liver and
into the bile and feces and (3) GSH’s ability to scavenge and
eliminate hydroxyl free radicals.
It is Well knoWn that excess exposures to heavy metals,
above the capacity of the normal cellular GSH capability to
bind and remove, inhibit the enzymes involved in the synthe

45

ciated thereWith, the treating compound has to be able to cross
the cellular membrane With ef?ciency and, if the brain is
involved, the treating compound must be able to cross the
blood brainbarrier. In order to be able to do this the compound
has to be quite hydrophobic in nature in order to be able to

50

sis of GSH and the recovery of oxidiZed GSH from GSSG

(oxidiZed glutathione) leading to decreased GSH levels that
are identi?ed as oxidative stress. Also, such heavy metal
excesses lead to an overproduction of free radicals by the
mitochondrial and further oxidiZes GSH to GSSG and
decreases the cells ability to remove toxins (organic and

each metal Would have different bond angles.
To be effective at treating both intracellular heavy metal

pass through the lipid bilayer of the cell membrane to reach
the site of heavy metal binding and intercept the ROS pro
duced by the mitochondria before they react and damage
cellular constituents. Further, the ideal treating compound
must be of very loW toxicity to cells and not disrupt mem
branes or biological pathWays and it should not be involved in

55

any natural metabolism that Would destroy its physical char
acter. In addition, the treating compound must be e?iciently
excreted from all tissues of the body in a non-toxic form. For

example, if the treating compound binds mercury cation

heavy metals) by the loWering of the intracellular concentra
tion of GSH. Therefore, an ideal Way to recover GSH levels

(Hg2+) it must carry this metal ion out of the body and not

Would be to develop a non-toxic compound With membrane

distribute it to other organs such as the kidney.

penetrating abilities, heavy metal binding properties and

60

reactive oxygen species scavenging properties that Were
superior to GSH.
With these properties a Well designed compound With both

heavy metal chelation properties and antioxidant properties
could; (I) easily penetrate cell membranes and the blood
brain barrier, (2) bind heavy metals preventing their inhibi
tion of enzymes needed to synthesiZe GSH and recover GSH

The ideal treatment compound must also exhibit stability
to air oxidation and breakdoWn so that the treating compound
can be effectively stored and packaged for delivery to the

patient in original, active form. The treating compound ide
ally must also be suited for ease of administration to a patient.
65

Further, the treating compound must not deplete the body of
essential metals such as Zinc and copper. In addition, it should

also have an adequately long plasma half-life such that it is

US 8,426,368 B2
4

3
possible to take eight hours rest and not have the treating

compound signi?cantly depleted from the plasma and tissues.
The present invention relates to methods of supplementing
the diet of a mammal, removing heavy metals and other toxins
from a mammal and ameliorating undesirable oxidative stress
in a mammal using a single molecule With cell membrane

penetrating abilities, metal chelation and oxygen radical
scavenging properties, and non-toxic character. To aid in
intraveneous delivery, some hydrophobic (lipophilic) com
pounds are made to be hydrophilic by formation of hydro

philic (Water soluble) analogs via attachment by disul?de
linkages that are converted after delivery by the body’ s reduc
ing capability back to the hydrophobic state. Other com
pounds have the reverse ability in that they are delivered as

hydrophobic esters and converted intracellular, by Well
knoWn esterases, into Water soluble, hydrophilic compounds
that are more excretable through the kidneys.
SUMMARY OF THE INVENTION

20

|\

In accordance With the purposes of the present invention as
described herein, a method of supplementing a diet of a

/

mammal is provided. That method comprises: administering
to said mammal a pharmaceutically effective amount of a

N
25

compound having a chemical formula:

CH3

.0

/

m

Where R1:

O

O

Where R3 :ethyl or methyl, R4Ihydro gen, glutathione, cys
65 teine, alphadihydrolipoic acid, cystamine, thiolphosphate,
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro

US 8,426,368 B2
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6

acetate or chloroacetate and n:2-4. The R4 attachment, other
than hydrogen, converts the hydrophobic base compound to a

-continued

hydrophilic, Water soluble compound. The R3 attachment
makes the base compound susceptible to esterase conversion
intracellular into a hydrophilic compound.
In accordance With yet another aspect of the present inven
tion, a method to remove heavy metals and toxins from a

mammal comprises: administering to said mammal a phar
maceutically effective amount of a compound having a
chemical formula:

10

Where R1:

30

45

50

Where R3 :ethyl or methyl, R4Ihydro gen, glutathione, cys

teine, alphadihydrolipoic acid, cystamine, thiolphosphate,
55

5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro
acetate or chloroacetate and n:2 -4. The R4 attachment, other
than hydrogen, converts the hydrophobic base compound to a

hydrophilic, Water soluble compound. The R3 attachment
60

makes the base compound susceptible to esterase conversion
intracellular into a hydrophilic compound.
In accordance With yet another aspect of the present inven
tion a method is provided for relieving oxidative stress in a

65

mammal. That method comprises: administering to said
mammal a pharmaceutically effective amount of a compound
having a chemical formula:

US 8,426,368 B2
8
-continued

m

Where R1:

—O

0

10

/\\N/
—N

and

H
N

O//S\
\O

,-

and

Where R3 :ethyl or methyl, R4:hydro gen, glutathione, cys

teine, alphadihydrolipoic acid, cystamine, thiolphosphate,
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro
acetate or chloroacetate and n:2 —4. The R4 attachment, other
than hydrogen, converts the hydrophobic base compound to a

hydrophilic, Water soluble compound. The R3 attachment
makes the base compound susceptible to esterase conversion
intracellular into a hydrophilic compound.
In accordance With yet another aspect of the present inven

tion, a pharmaceutical composition is provided comprising:
50

a pharmaceutically effective amount of a compound hav
ing a chemical formula:

Where R1:

US 8,426,368 B2
9

10

-continued

-continued
H
N
m

25

30

Where R3 :ethyl or methyl, R4:hydro gen, glutathione, cys

teine, alphadihydrolipoic acid, cystamine, thiolphosphate,
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro

0
35

||

@
W

O>

acetate or chloroacetate and n:2-4; The R4 attachment, other
than hydrogen, converts the hydrophobic base compound to a

hydrophilic, Water soluble compound. The R3 attachment
makes the base compound susceptible to esterase conversion
intracellular into a hydrophilic compound. and

,

40

a pharmaceutically acceptable excipient.
In accordance With yet another aspect of the present inven

tion, a pharmaceutical composition is provided comprising:

N—N

45

betWeen about 99.5 and about 5 Weight percent of a phar
maceutically effective amount of a compound having a
chemical formula:

\

,

l/

>N,

50

Where R1:

55

\

65
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12

-continued

-continued

—N

m

\N /

and

H
N

S

O// \\O
and

Where R2:
O

HO

OH,\_/,

O

V
20

0

Where R3 :ethyl or methyl, R4:hydro gen, glutathione, cys
25

teine, alphadihydrolipoic acid, cystamine, thiolphosphate,
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro
acetate or chloroacetate and n:2-4; The R4 attachment, other
than hydrogen, converts the hydrophobic base compound to a

30

II

makes the base compound susceptible to esterase conversion
intracellular into a hydrophilic compound.
betWeen about 0.0 and about 50 Weight percent of an addi

o

\gl/

hydrophilic, Water soluble compound. The R3 attachment

35

tional antioxidant;
betWeen about 0.0 and about 20 Weight percent of a Water

soluble metal chelator;
betWeen about 0.0 and about 50 Weight percent of glu

tathione;
40

betWeen about 0.0 and about 50 Weight percent of an addi

tional dietary supplement that supports glutathione synthesis;

\

l/

and
betWeen about 0.5 and about 50 Weight percent of a phar
45

maceutically acceptable excipient.
In the following description there is shoWn and described
several different embodiments of the invention, simply by
Way of illustration of some of the modes best suited to carry

50

55

out the invention. As it Will be realiZed, the invention is
capable of other different embodiments and its several details
are capable of modi?cation in various, obvious aspects all
Without departing from the invention.
DETAILED DESCRIPTION OF THE PREFERRED
EMBODIMENTS OF THE INVENTION

The present invention relates to various methods of supple
menting the diet of a mammal, removing heavy metals and
60

other toxins from a mammal and relieving or ameliorating
oxidative stress in a mammal. Each of the methods relies upon

administering to said mammal a pharmaceutically effective
amount of a compound having a chemical formula:
65
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13
Where R1:

-continued

/ |

20

and

25

30

and

Where R2:
0

0

40

Where R3 :ethyl or methyl, R4:hydro gen, glutathione, cys

teine, alphadihydrolipoic acid, cystamine, thiolphosphate,
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro
45

acetate or chloroacetate and n:2 -4. The R4 attachment, other
than hydrogen, converts the hydrophobic base compound to a

hydrophilic, Water soluble compound. The R3 attachment
makes the base compound susceptible to esterase conversion
intracellular into a hydrophilic compound. The active com
50

pounds and their synthesis are described in detail in copend
ing U.S. patent application Ser. No. 12/731,415 ?led Mar. 25,
2010, the full disclosure of Which is incorporated herein by
reference.

55

The pharmaceutically effective amount of the compounds
in question may be administered in any appropriate manner
including, but not limited to, oral administration, transdermal
administration, nasal administration, intravenous admini stra

tion and administration by suppository. The method of
60

supplementing a diet of a mammal includes administering
betWeen about 0.5 and about 40.0 mg of the compound per

kilogram of the mammal’s total body Weight per day
although, due to the lack of toxicity higher dose levels are
acceptable. The compound may be administered in combina
65

tion With another antioxidant or chelator. That antioxidant
may be selected from a group including but not limited to

vitamin-E, vitamin-D, cysteine, cystine, glutathione, lipoic
acid and combinations thereof.

US 8,426,368 B2
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In the method of removing heavy metals and other toxins

benzoate, a food preservative) and many other benzoates, and
other more complex carboxylated aromatic ring systems, are

from a mammal, the compound is administered in an amount
betWeen about 0.5 and about 60.0 mg per kilogram of the

mammal’s total body Weight per day. In this method the

not usually toxic due to their hydrophilic nature and ease of
excretion.

compound may be administered With a Water soluble metal
chelator. That Water soluble metal chelator may be selected

Advantageously the base compounds With hydrogen at R4,
are lipid soluble and, accordingly, after entering the plasma

from a group consisting of glutathione (GSH), dihydrolipoic

can enter cells of all tissues, cross the blood brain barrier and

acid (DLPA), lipoic acid (LPA), N-acetylcysteine (NAC),
dimercaptopropane sulfonate (DMPS), dimercaptosuccinic

enter the bone marroW. This is important because the damage

caused by heavy metals and the oxidative stress produced by

acid (DMSA), ethylenediaminetetraacetic acid (EDTA), and

hydroxyl free radicals and other free radicals of the reactive
oxygen species mostly occur in the intracellular space. In

mixtures thereof. It should be appreciated, hoWever, that other
Water soluble metal chelators besides those listed could be
utilized.
In the method of relieving oxidative stress in a mammal the

contrast, most dietary antioxidants are Water soluble and can
not enter into cells effectively nor can they cross the blood/

brain barrier. As a further advantage, the lipid solubility of the

compound may be administered orally, transderrnally,

compounds increases the time they spend in the body alloW

nasally, intravenously, injected subcutaneously, by supposi

ing them to be more effective at chelating heavy metals and

tory and other appropriate methods. Typically the compound

scavenging hydroxyl free radicals. Chemical attachment of

is administered in an amount of betWeen about 0.5 and about

charged, natural compounds through the disul?de linkage
produces Water soluble analogs (for intravenous application)

100.0 mg of the compound per kilogram of the mammal’s

total body Weight per day. The exceptionally loW level of

20

mammalian toxicity Would also alloW higher doses to be used
in cases of acute toxicity or high oxidative stress. Here, it
should also be noted that the present method may be used to
treat oxidative stress resulting from virtually any cause or

source including, but not limited to, heavy metal toxicity,

taining the methylester and ethylester linkages offer the
advantage of being made into charged Water soluble species
25

drugs such as acetaminophen, xenobiotics, aging, infection,
physical injury and disease.

ellular glutathione and Work primarily by salvaging naturally

activity, Which may have advantages for excretion through the
30

kidneys.
The compounds do not detectably disrupt any biochemical
process in a mammal. They simply partition into the hydro

oxidized glutathione (GSSG). Also, the inhibitory binding of
Hg2+ and Pb2+ and their removal from enzyme involved in the

synthesis (e.g. glutatmine synthetase) and recovery of GSH
(e.g. glutathione reductase) Would additionally aid in the

by enzymatic action of the natural esterases found in the
mammalian body. This compound form starts out hydropho
bic, can penetrate cell membranes after Which it is convertible
to the charged Water soluble species by intracellular esterase

These compounds are not used to directly produce intrac

produced reduced glutathione (GSH) by the process of scav
enging the intracellular ROSs preventing the oxidation to

of the base compounds Which Would be rapidly reduced in the
blood back to the original hydrophobic compounds and alloW
cell membrane permeation. Additionally, compounds con

phobic areas, bind heavy metals, react With free radicals
eliminating them and are then excreted from the body prima
35

rily through the biliary transport system of the liver. The

recovery of GSH to optimal levels. In accordance With an

pharmaceutical compositions of the present invention are

additional aspect of the present invention the compound may
be administered With a precursor of glutathione. That glu

characterized by having relatively high ORAC (Oxygen

tathione precursor may be selected from a group of precursors

measured by a compound or composition’s ability to enter
separate reactive oxygen species or free radicals and prevent
them from oxidizing a Water soluble ?uorescent vitamin-E

consisting of cysteine, N-acetylcysteine, glycine, glutamate

Radical-Absorbance-Capacity) scores. The ORAC score is
40

and combinations thereof. Also, removal of heavy metals
from the iron-sulfur centers and other elements of the mito

chondrial electron transport system Would dramatically
reduce the mitochondrial production of hydroxyl free radi
cals. It is Well knoWn that heavy metals make the mitochon
dria into hydroxyl free radical producing species Where one
heavy metal atom can cause the production of orders of mag

nitude higher levels of hydroxyl free radicals.
In yet another possible embodiment the compound is
administered With a dietary supplement that supports glu
tathione synthesis. Such dietary supplements include, but are

45

they exist and react With free radicals more effectively

thereby scavenging the hydroxyl free radicals and preventing
them from doing damage. Signi?cantly, vitamin-E has been
50

not limited to, Whey protein, N-acetylcysteine, cysteine, glu
tathione, nicotine adenine dinucleotide (NAD+), reduced
nicotine adenine dinucleotide (NADH), glycylcysteine (gly
cyc), glutamylcysteine (glu-cys), and combinations thereof.

cals. The pharmaceutical compositions of the present inven
55

should provide even better protection. Mass Spectrometry

60

as sul?tes (iSO3_) Which are charged and eliminated

through the kidneys.
The pharmaceutical compositions of the present invention

attached to the sulfhydryl containing chains via an amide

aromatic carboxylate. Benzocarboxylate (e.g. monosodium

human and rat liver homogenates have shoWn that the major
products produced Were those With tWo and three oxygen
atoms attached to the terminal sulfhydryl groups. This Would

convert the sulfhydryl (iSH) to higher oxidized levels such

urine tests commonly used to measure human health. This
loW toxicity is attributed to the fact that the aromatic rings are

matic system. Any cleavage of this bond Would produce an

vitamin E and, accordingly, the pharmaceutical compositions
evaluations of some of the compounds after incubation With

methods of (a) supplementing the diet, (b) removing heavy

connection that contains a carboxylate attached to the aro

recommended for Alzheimers diseased subjects to prevent
oxidizing damage to their brain membranes or membrane
lipids due to vitamin’s E reactivity With hydroxyl free radi
tion are more capable of reacting With these radicals than

The compounds used in the present invention provide a
number of unique bene?ts that make them attractive for use in

metals and other toxins and (c) ameliorating oxidative stress
in mammals. Many of the compounds exhibit very loW if any
toxicity and do not adversely affect commonly used blood/

derivative. The pharmaceutical compositions of the present
invention have the ability in the body to protect vitamin E (a
fat soluble vitamin) and other fat soluble natural compounds
such as lipids from damage by oxidizing free radicals since
the compositions partition into the hydrophobic areas Where

65

are also characterized by an ability to increase the reduced
(GSH) over oxidized (GSSG) glutathione ratio as Well as to
increase the total glutathione in the Whole blood. Thus, more

US 8,426,368 B2
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glutathione is available to scavenge free radicals and participate in the p-450 system to remove insoluble organic toxins
from the membranes and cells. Thus, the body is better able to
maintain a healthy glutathione level When the diet of the
mammal is supplemented With compositions of the present 5
invention.

-Continued

Further, the pharmaceutical compositions of the present
invention are characterized by good stability When stored.
They also generally exhibit a very loW odor level thereby 10
making them more palatable for oral administration.

Generally, the pharmaceutical compositions of the present
invention are better than glutathione delivered by IV or trans

dermally for increasing the intracellular level of glutathione.
The rationale behind this is based on the very loW level of 15

glutathione found in the plasma versus the intercellular levels
Which are one thousand to ten thousand times higher. Any

glutathione molecule that enters the blood by IV or transder

mal delivery is immediately bound and removed by the glu
tathione receptors in the liver that are used to take glutathione
labeled toxins and viruses out of the plasma and place them in

the bile (biliary transport system). Glutathione in the blood
Would not remain long enough to enter cells Where it could be

used, plus do to its highly charged character (2 negative and 1

25

positive charges/molecule) GSH Would have to enter via spe
ci?c carriers in the face of a signi?cant concentration gradient
that Would prevent this. This statement is based on the fact
that many Water insoluble toxicants are removed from the

body by ?rst oxidiZing them, attaching glutathione (by the 30
enZyme glutathione-s-transferase) to this oxidiZed site on the

toxin, then actively transporting the glutathione labeled toxi
cant out of the cell and into the blood Where it is actively

removed by the glutathione receptors of the biliary transport
system. In contrast, pharmaceutical compositions of the 35
present invention face no concentration gradients and can
enter all cells and due to their hydrophobic nature, insert to

some degree into the lipid membrane or other hydrophobic
sites Where they can scavenge hydroxyl free radicals, the
major chemical species that oxidiZe glutathione and cause its

levels to drop. The pharmaceutical compositions salvage
naturally produced glutathione intracellular enhancing its
longevity and raising glutathione levels in-vivo Without hav
ing to battle transport across a membrane against a high

gradient of glutathione.

45

Pharmaceutical compositions of the present invention may

be prepared by combining a pharmaceutically effective

I

amount of a compound having a chemical formula:

,

,

50

55

Where R1:

I

\N

60

N

CH3

E?s

(l
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-continued

that supports glutathione synthesis may be utiliZed including
but not limited to Whey protein, N-acetylcystein, cysteine,
glutathione, nicotine adenine dinucleotide (NAD+), reduced
nicotine adenine dinucleotide (NADH), glycylcysteine (gly
cys), glutamylcysteine (glu-cyc), and combinations thereof.

H
N

Pharmaceutical compositions may also include various bind

ers, preservatives, mineral supplements, bulking agents, dilu
ents, carriers, ?avoring agents that are Widely knoWn to be

used in pharmaceutical compositions. Exemplary pharma
ceutical compositions include betWeen about 95.5 and about
85 Weight percent active compound, betWeen about 0.5 and

about 15 Weight percent excipient. The optional additional
antioxidant(s) may be provided at betWeen about 0 and about
50 Weight percent. The optional additional Water soluble
metal chelator may be provided at betWeen about 0 and about

20 Weight percent. The optional additional precursor of glu
tathione may be provided at betWeen about 0 and about 50

Weight percent. Further the optionally additional dietary
supplement that supports glutathione synthesis may be pro
20

25

vided at betWeen about 0 and about 50 Weight percent. One or
more of any of the optional additives may be included. The

optional additive replaces a like percentage of the compound
in the ?nal composition.
Preferred dosage forms for oral administration include the
isolated compounds in poWder form. Such poWders may be
taken up With a scoup and spread onto food or mixed into

drinks for easy consumption Without bad taste. The pure

compounds may be pre-mixed With certain dietary ingredi
ents such as butter, olive oil, corn oil, albumin, Whey or other

Where R3 :ethyl or methyl, R4:hydrogen, glutathione, cys

30

mere process of dissolving them. It has been determined that

teine, alphadihydrolipoic acid, cystamine, thiolphosphate,
5'thioladenosine, L-homocysteine, co-enZyme A, 2-mercap
toethanol, dithiothreitol, iodoacetate, bromoacetate, ?uoro
acetate or chloroacetate and n 2-4, With an excipient. Sub

35

stantially any suitable excipient may be utilized including but
not limited to albumin, almond oil, ascorbic acid, benZoic
acid, calcium stearate, canola oil, calcium carboxymethylcel
40

seed oil, cyclodextrins, ethylene glycol palmitostearate, gela
tin, glycerin, hydroxyethyl cellulose, hydroxyethylmethyl
cellulose, hydroxypropyl cellulose, hypermellose, loW-sub
stituted hydroxypropyl cellulose, lanolin, linoleic acid, mag
nesium silicate, magnesium stearate, medium-chain triglyc
erides, mineral oil, olive oil, peanut oil, pectin, compressible
sugar, sun?ower oil, hydrogenated vegetable oil, Water and

glycol, Soluphor P and NMP; (b) PEG derivatives such as

Cremophor RH40, Cremophor EL/ELP and Solutol HS-l5;
and (c) polyoxamers such as Lutrol F68, Lutrol F127, Lutrol
45

50

min-E, vitamin-D, cystine, glutathione, lipoic acid and com
binations thereof. Further the pharmaceutical compositions
may include a Water soluble metal chelator to enhance

removal of toxic metals both through the liver and kidney and
55

soluble metal chelator may be utiliZed including but not lim

ited to glutathione (GSH), dihydrolipoic acid (DLPA), lipoic
acid (LPA), N-acetylcysteine (NAC), dimercaptopropane sul
fonate (DMPS), dimercaptosuccinic acid (DMSA), ethylene
diaminetetraacetic acid (EDTA), and mixtures thereof. Fur
ther, in order to further enhance the levels of glutathione in the
subject, the pharmaceutical compositions may include a pre

synthesis. Substantially any appropriate dietary supplement

ate) to provide a mixed material that can be ef?ciently encap
sulated by machines for mass production at a rapid rate.
The pure compound may also be made into tablet form by
mixing With common agents or binders used to induce adhe

sive properties for tablet formation.
Any of the other hydrophobic compounds may be dis
solved in simple oils and applied to the skin. The compounds
dissolved in DMSO (dimethylsulfoxide) are rapidly taken up
through the skin Without local irritation. Also, dissolving the
compounds in Warm butter alloWs them to be applied trans

60

dermally.
The compounds may be placed in suppository capsules
either in poWder form or dissolved in oils or as mixed With

cursor of glutathione Which may be selected from a group

including but not limited to cysteine, glycine, glutamate and
combinations thereof. Further pharmaceutical compositions
may include a dietary supplement that supports glutathione

Micro 68 and Lutrol Micro 127.

The pure compound may be encapsulated in several Weight
forms (eg. 50, 100, 200, 500 mg/capsule) and taken orally.
The pure compound may be mixed With excipients (eg.
microcrystalline cellulose, hyper'mellose, magnesium stear

combinations thereof. In order to provide multiple antioxi

With an enhanced rate. Substantially, any suitable Water

be used for parenteral (inj ectible), oral, topical or intranasal
delivery in different combinations and ratios according to
need include: (a) co-solvents such as polyethylene glycol

300/400, Macrogol 300/400, Lutrol E300/E400, propylene

dant potential, the pharmaceutical compositions may further
include other antioxidants including, but not limited to vita

it takes about tWo hours post ingestion for the maximum level
of active ingredient to shoW up in the plasma of all tested
animals. Further, after 24 hours post-ingestion the active
ingredient levels Were shoWn to drop between 4-12% of the
peak values seen at hour 2.
Some of the commercially available solubiliZers that can

lulose, sodium carboxymethylcellulose, castor oil, hydroge
nated castor oil, microcrystalline cellulose, corn oil, cotton

foods Which Will help in absorption of the compounds by the

65

protein based material (eg. human serum albumin, HSA) for
delivery. The compounds may also be dissolved in human
serum albumin for intravenous delivery. Similarly, blood
could be pulled from a patient and the compounds added to
that blood before being returned to the patient. This property
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1. Prepare a 1:1 W/v of ethyl alcohol and Cremophor.
2. Weigh out the required amount of OSR#1 poWder.

is allowed as HSA is a Water soluble protein With hydropho
bic areas designed to carry natural hydrophobic molecules
through the blood to cells Where they are transferred to cell
membranes.

3. Add the required amount to the 1:1 mixture.
4. Vortex to make sure OSR is in solution.
5. Sonicate if necessary for a feW minutes.

The compositions and methods of the present invention
may be accomplished by various means Which are illustrated
in the examples beloW. These examples are intended to be
illustrative only as numerous modi?cations and variations
Will be apparent to those skilled in the art.

6. SloWly add Normal Saline 50 to 80% of the ?nal volume.
EXAMPLE 8

A dosing solution for intravenous administration (IV) into

EXAMPLE 1

test animals Was prepared at 1 mg/mL in a formulation con

Compounds have been produced and used by test animals
and humans in pure poWder form in resealable plastic bags

sisting of 80% normal saline (NS) and 20% of a 1:1 mixture
of N-methylpyrrolidone (NMP) and Solutol HS15. This Was
used successfully to determine the plasma half life of one of
the compounds in mice.

accompanied With a pharmaceutical spoon that alloWs deliv
ery of compound at 50 to 100 mg/ spoonful. The pure poWder
can be taken directly into the oral cavity for sublingual deliv
ery or mixed With foods and drinks. The mixing of these

EXAMPLE 9

compounds has been done With oily foods such as butter, olive
oil, peanut butter to enhance their solubiliZation prior to

ingestion and uptake in the digestive tract.

20

EXAMPLE 2

Compounds have been mixed With excipients magnesium
stearate, microcrystalline cellulose, hypermellose and silicon
dioxide to form a pharmaceutical composition administered

Medicament and/ or preparation of dosage form. To prepare
a medicament and/or suitable dosage form, the pharmaceuti
cally active compound of the invention may be admixed and/
or contacted With one or more of the excipients listed in Table
9-1 .

25

TABLE 9-1

in capsules of 50, 100 and 200 mg quantities of compound for

Excipi ents

oral ingestion by humans.

Acacia
Acesulfame Potassium

EXAMPLE 3
30

Acetic Acid, Glacial
Acetone

Compounds have been dissolved in natural oils such as

olive oil, cod liver oil, corn oil, butter and taken orally by

Acetyltributyl Citrate
Acetyltriethyl Citrate

humans.

Agar
EXAMPLE 4

Compounds have been dissolved in natural oils such as
olive oil, cod liver oil, corn oil, butter and applied to the skin
With rubbing to affect a transdermal delivery of the compound
into humans.

35

Alitame
Almond Oil

Alpha Tocopherol
40

Ammonium Al ginate
Ascorbic Acid
45

50

Bentonite
Benzalkonium Chloride
Benzethonium Chloride
Benzoic Acid

Benzyl Alcohol
Benzyl Benzoate

ery into test animals as folloWs:

Boric Acid

1. Prepare 1:1 W/v of NMP and Solutol HS 15

2. Weigh out the required amount of the pharmaceutically
55

3. Add required amount of the 1:1 mixture. (20% of ?nal

Bronopol
Butylated Hydroxyanisole
Butylated Hydroxytoluene
Butylparaben
Calcium Al ginate

volume)

Calcium Carbonate

4. Vortex to make sure that the compound is in solution.

5. SloWly add the Normal saline (80% of ?nal volume)
6. Sonicate for a feW minutes to get a clear solution.

60

EXAMPLE 7

Pharmaceutically effective compounds of the invention
have been dissolved in Cremophor and ethyl alcohol mixtures
for both subcutaneous and intravenous delivery into test ani
mals as folloWs:

Ascorbyl Palmitate

Aspartame
Attapulgite

EXAMPLE 6

effective compound in poWder form.

Aluminum Oxide
Aluminum Stearate
Ammonia Solution

results.

Compounds have been dissolved in Solutol HS 15 and
NMP mixtures for both subcutaneous and intravenous deliv

Aluminum Hydroxide Adjuvant
Aluminum Phosphate Adjuvant

Compounds have been dissolved in DMSO (dimethylsul
injected subcutaneously into test animals With excellent

Alginic Acid

Aliphatic Polyesters

EXAMPLE 5

foxide):isotonic sodium chloride (25%:75% mixtures) and

Albumin
Alcohol

65

Calcium Phosphate, Dibasic Anhydrous
Calcium Phosphate, Dibasic Dihydrate
Calcium Phosphate, Tribasic
Calcium Stearate
Calcium Sulfate
Canola Oil
Carbomer
Carbon Dioxide

Carboxymethylcellulose Calcium
Carboxymethylcellulose Sodium

Carrageenan
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TABLE 9- 1 -continued

TABLE 9-1 -c0ntinued

Excipients
Castor Oil
Castor Oil, Hydrogenated

Excipients
5

Hydroxypropyl Cellulose, LoW-substituted
Hydroxypropyl Starch

Cellulose, Microcrystalline

Hyprornellose

Cellulose, Powdered

Hyprornellose Acetate Succinate

Cellulose, Silici?ed Microcrystalline

Hyprornellose Phthalate

Cellulose Acetate
Cellulose Acetate Phthalate
Ceratonia

Irnidurea
Inulin
Iron Oxides

10

Cetostearyl Alcohol
Cetrirnide

Isornalt
Isopropyl Alcohol

Cetyl Alcohol

Isopropyl Myristate

CetylpyridiniuIn Chloride

Isopropyl Palrnitate

Chitosan
Chlorhexidine
Chlorobutanol

Kaolin
Lactic Acid
Lactitol

15

Chlorocresol
Chlorodi?uoroethane (HCFC)
Chlorofluorocarbons (CFC)
Chloroxylenol
Cholesterol
Citric Acid Monohydrate
Colloidal Silicon Dioxide

Lactose, Anhydrous
Lactose, Monohydrate
Lactose, Spray-Dried
Lanolin
Lanolin, Hydrous
20

Coloring Agents
Copovidone

Lanolin Alcohols
Lauric Acid

Lecithin
Leucine

Corn Oil

Linoleic Acid

Cottonseed Oil

Macrogol 15 Hydroxystearate

Cresol
Croscarrnellose Sodiurn

25

Crospovidone
Cyclodextrins
Cyclornethicone

MagnesiuIn Oxide
MagnesiuIn Silicate
MagnesiuIn Stearate

Denatoniurn BenZoate
Dextrates
Dextrin
Dextrose

MagnesiuIn Trisilicate
30

Dibutyl Phthalate
Dibutyl Sebacate
Diethanolalnine
Diethyl Phthalate

Malic Acid
Maltitol
Maltitol Solution

Maltodextrin
Maltol
35

Difluoroethane (HFC)
Dirnethicone
Dirnethyl Ether
Dirnethyl Phthalate
Dirnethyl Sulfoxide
Dirnethylacetalnide
Disodiurn Edetate

MagnesiuIn AlUIHlHUIH Silicate
MagnesiuIn Carbonate

Maltose
Mannitol

Mediurn-chain Triglycerides
MegluInine
Menthol
Methylcellulose
Methylparaben
Mineral Oil
40

Docusate SodiuIn
Edetic Acid

Mineral Oil, Light
Mineral Oil and Lanolin Alcohols
Monoethanolalnine

Erythorbic Acid

MonosodiuIn Glutalnate

Erythritol

Monothioglycerol

Ethyl Acetate
Ethyl Lactate
Ethyl Maltol

45

Ethyl Oleate

Myristic Acid
Neohesperidin Dihydrochalcone
Nitrogen
Nitrous Oxide

Ethyl Vanillin

Octyldodecanol

Ethylcellulose

Oleic Acid

Ethylene Glycol Palrnitostearate
Ethylene Vinyl Acetate
Ethylparaben

Oleyl Alcohol
50

Fructose
Furnaric Acid
Gelatin

Glucose, Liquid
Glycerin
Glyceryl Behenate

Olive Oil
Palrnitic Acid
Paraf?n
Peanut Oil
Pectin

55

Petrolaturn and Lanolin Alcohols
Petrolaturn
Phenol

Glyceryl Monooleate

Phenoxyethanol

Glyceryl Monostearate
Glyceryl Palrnitostearate
Glycofurol

Phenylethyl Alcohol
Phenylrnercuric Acetate
Phenylrnercuric Borate

Guar Gurn
Hectorite

60

Phenylrnercuric Nitrate
Phosphoric Acid

Hepta?uoropropane (HFC)

Polacrilin Potassiurn

Hexetidine

PoloxaIner

Hydrocarbons (HC)

Polycarbophil

Hydrochloric Acid
Hydroxyethyl Cellulose
Hydroxyethylrnethyl Cellulose
Hydroxypropyl Cellulose

Polydextrose
Polyethylene Glycol
Polyethylene Oxide

65

Polyrnethacrylates
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TABLE 9-1-continued

TABLE 9-1 -continued

Excip ients

Excipi ents

Poly(methyl vinyl ether/maleic anhydride)
Polyoxyethylene Alkyl Ethers

Triethanolamine

Triethyl Citrate

Polyoxyethylene Castor Oil Derivatives
Polyoxyethylene Sorbitan Fatty Acid Esters

Vanillin

Vegetable Oil, Hydrogenated

Polyoxyethylene Stearates
Polyvinyl Acetate Phthalate
Polyvinyl Alcohol
Potassium Alginate
Potassium
Potassium
Potassium
Potassium

Water

Wax, Anionic Emulsifying
Wax, Carnauba
Wax, Cetyl Esters

BenZoate
Bicarbonate
Chloride
Citrate

Wax, Microcrystalline
Wax, Nonionic Emulsifying
Wax, White
Wax, YelloW

Potassium Hydroxide
Potassium Metabisul?te
Potassium Sorbate
Povidone

Xanthan Gum

Xylitol

Propionic Acid
Propyl Gallate
Propylene Carbonate

Propylene Glycol
Propylene Glycol Alginate
Propylparaben
2-Pyrrolidone

Zein
Zinc Acetate
Zinc Stearate
20

EXAMPLE 10

Saccharin
Saccharin Sodium

Saponite

25

Sesame Oil
Shellac
Simethicone
Sodium Acetate

tion may be chosen from among the dosage forms listed in
Table 10-1.

Sodium Alginate
Sodium Ascorbate
Sodium BenZoate
Sodium Bicarbonate
Sodium Borate
Sodium Chloride

Sodium Citrate Dihydrate
Sodium Cyclamate
Sodium Hyaluronate
Sodium Hydroxide

Dosage form. A suitable dosage form for administration of
the pharmaceutically active compound of the present inven

30

TABLE 10-1
Dosage forms
NAME

DEFINITION

AEROSOL

A product that is packaged under pressure and
contains therapeutically active ingredients that are

35

Sodium Lactate

released upon activation of an appropriate valve

Sodium Lauryl Sulfate

system; it is intended for topical application to the

Sodium Metabisul?te

skin as Well as local application into the nose

Sodium Phosphate, Dibasic
Sodium Phosphate, Monobasic
Sodium Propionate
Sodium Starch Glycolate
Sodium Stearyl Fumarate

(nasal aerosols), mouth (lingual aerosols), or lungs

40

(inhalation aerosols).
AEROSOL,
POWDER

A product that is packaged under pressure and
contains therapeutically active ingredients, in the
form of a poWder, that are released upon

Sodium Sul?te
Sorbic Acid

Starch

activation of an appropriate valve system.
A solid dosage form usually in the form ofa
rectangle that is meant to be cheWed.
A solid oral dosage form consisting of a shell and
a ?lling. The shell is composed ofa single sealed
enclosure, or tWo halves that ?t together and

Starch, PregelatiniZed

Which are sometimes sealed With a band. Capsule

Sorbitan Esters (Sorbitan Fatty Acid Esters)

BAR, CHEWABLE
45

Sorbitol

CAPSULE

Soybean Oil
Starch, SteriliZable Maize
Stearic Acid

shells may be made from gelatin, starch, or
cellulose, or other suitable materials, may be soft

50

Stearyl Alcohol

or hard, and are ?lled With solid or liquid

Sucralose
Sucrose

CAPSULE,

ingredients that can be poured or squeezed.
A solid dosage form in Which the drug is enclosed

Sugar, Compressible

COATED

Within either a hard or soft soluble container or

Sugar, Confectioner’s

Sugar Spheres
Sulfobutylether [5-Cyclodextrin

“shell” made from a suitable form of gelatin;

additionally, the capsule is covered in a designated

55

Sul?aric Acid

Suppository Bases, Hard Fat

coating.
CAPSULE,

A solid dosage form in Which the drug is enclosed

COATED

Within either a hard or soft soluble container or

PELLETS

“shell” made from a suitable form of gelatin; the

Talc
Tartaric Acid

drug itself is in the form ofgranules to Which

CAPSULE,

varying amounts of coating have been applied.
A solid dosage form in Which the drug is enclosed

Thaumatin

COATED,

Within either a hard or soft soluble container or

Thymol

EXTENDED

“shell” made from a suitable form of gelatin;

Titanium Dioxide

RELEASE

additionally, the capsule is covered in a designated
coating, and Which releases a drug (or drugs) in

Tetra?uoroethane (HFC)

60

Tragacanth
Trehalose
Triacetin

Tributyl Citrate

such a manner to alloW at least a reduction in

65

dosing frequency as compared to that drug (or
drugs) presented as a conventional dosage form.
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TABLE 10-1 -continued

TABLE 10-1-c0ntinued

Dogge forms

Dogge forms

NAME

DEFINITION

CAPSULE,

A solid dosage form in Which the drug is enclosed

5

DELAYED
RELEASE

Within either a hard or soft soluble container made
from a suitable form of gelatin, and Which releases
a drug (or drugs) at a time other than promptly
after administration. Enteric-coated articles are

CAPSULE,

delayed release dosage forms.
A solid dosage form in Which the drug is enclosed

NAME

DEFINITION

EXTRACT

A concentrated preparation of vegetable or animal
drugs obtained by removal of the active
constituents of the respective drugs With a suitable
menstrua, evaporation of all or nearly all of the
solvent, and adjustment of the residual masses or

10
FIBER,

poWders to the prescribed standards.
A slender and elongated solid thread-like

DELAYED

Within either a hard or soft soluble container or

EXTENDED

substance that delivers drug in such a manner to

RELEASE

“shell” made from a suitable form of gelatin; the

RELEASE

alloW a reduction in dosing frequency as

PELLETS

drug itself is in the form of granules to Which

compared to that drug (or drugs) presented as a

enteric coating has been applied, thus delaying

conventional dosage form.

CAPSULE,

release of the drug until its passage into the
intestines.
A solid dosage form in Which the drug is enclosed

EXTENDED

Within either a hard or soft soluble container made

RELEASE

from a suitable form of gelatin, and Which releases

15 FILM, SOLUBLE

FOR SOLUTION

prior to administration.

FOR SUSPENSION A product, usually a solid, intended for suspension

a drug (or drugs) in such a manner to alloW a

reduction in dosing frequency as compared to that
drug (or drugs) presented as a conventional dosage
CAPSULE, FILM
COATED,

form.
A solid dosage form in Which the drug is enclosed
Within either a hard or soft soluble container or

EXTENDED

“shell” made from a suitable form of gelatin;

RELEASE

additionally, the capsule is covered in a designated
?lm coating, and Which releases a drug (or drugs)

prior to administration.

FOR
20 SUSPENSION,
EXTENDED
RELEASE
GEL

CONCENTRATE
CORE,
EXTENDED

administered, the drug Will be released at a
constant rate over a speci?ed period.
A semisolid3 dosage form that contains a gelling

colloidal dispersion.4 A gel may contain
suspended particles.

25

in such a manner to alloW at least a reduction in

CAPSULE,
LIQUID
FILLED

A product, usually a solid, intended for suspension
prior to administration; once the suspension is

agent to provide stiffness to a solution or a

GLOBULE

dosing frequency as compared to that drug (or
CAPSULE,
GELATIN
COATED

A thin layer or coating Which is susceptible to
being dissolved When in contact With a liquid.
A product, usually a solid, intended for solution

Also called pellets or pilules, are made of pure

sucrose, lactose, or other polysaccharides. They

drugs) presented as a conventional dosage form.

are formed into small globular masses of various

A solid dosage form in Which the drug is enclosed
Within either a hard or soft soluble container made
from a suitable form of gelatin; through a banding
process, the capsule is coated With additional
layers of gelatin so as to form a complete seal.
A solid dosage form in Which the drug is enclosed
Within a soluble, gelatin shell Which is plasticiZed

sizes, and are medicated by placing them in a vial
and adding the liquid drug attenuation in the
proportion not less than one percent (v/W). After
shaking, the medicated globules are dried at
temperatures not to exceed 40 degrees Centigrade.
A small particle or grain.
A small medicinal particle or grain to Which an

by the addition of a polyol, such as sorbitol or
glycerin, and is therefore of a someWhat thicker
consistency than that of a hard shell capsule;
typically, the active ingredients are dissolved or

suspended in a liquid vehicle.
A liquid preparation of increased strength and
reduced volume Which is usually diluted prior to
administration.
An ocular system placed in the eye from Which the

30

GRANULE
GRANULE,
DELAYED
35 RELEASE

GRANULE,
EFFERVESCENT

40

sodium bicarbonate, citric acid, and tartaric acid
Which, When in contact With Water, has the
capability to release gas, resulting in
effervescence.
A small medicinal particle or grain made available

RELEASE

drug diffuses through a membrane at a constant
rate over a speci?ed period.

CREAM

An emulsion, semisolid3 dosage form, usually

With solvent just before dispensing; the granules

containing >20% Water and volatiles5 and/or <50%
hydrocarbons, Waxes, or polyols as the

are so prepared to contain not only the medicinal
agent, but the colorants, ?avorants, and any other

vehicle. This dosage form is generally for

GRANULE, FOR
SOLUTION

enteric or other coating has been applied, thus
delaying release of the drug until its passage into
the intestines.
A small particle or grain containing a medicinal
agent in a dry mixture usually composed of

45

external application to the skin or mucous
membranes.

CREAM,
AUGMENTED

desired pharmaceutic ingredient.
GRANULE, FOR
SUSPENSION

A cream dosage form that enhances drug delivery.
Augmentation does not refer to the strength of the
drug in the dosage form. NOTE: CDER has
decided to refrain from expanding the use of this

50

ingredient.

criteria that must be met to be considered

SYSTEM

GRANULE, FOR

SUSPENSION,

in its more stable dry form, to be reconstituted

Modern technology, distributed With or as a part

EXTENDED

With Solvent lust b?fom disp?nsing to £01m a

of a ding product that allows for the uniform

RELEASE
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.

.

oftime and maintains constant drug levels in the
blood or targ?t US$116‘

.

medicinal agents; it is intended for oral use.

. .

INJECTABLE,

An injection, Which either consists of or forms

LIPOSOMAL

liposomes (a lipid bilayer vesicle usually

.

.

.

A dosage form consisting ofa tWo-phase system
,

,

,

,

,

,

ofwhlch 1S dlspersfd as droplfts (mtfmal or

.

.

. .

l

.

.

composed ofphospholipids Which is used to

comprised of at least tWo immiscible liquids , one

?ncapsulat? an activ? drug Substanc6>_
60 INJECTION

disp?rs?d P115156) Within the other liquid (External

ENEMA

suspension; the extended release system achieves

sloW release ofthe ‘drug over an extended period

A 016m, pl?asantly ?avomd, swwten?d
hydroalcoholic liquid containing dissolved
. .

EMULSION

A small medicinal particle or grain made available

“augm@nt@d”_

ml?as? or targeting of drugs to th6 body
ELIXIR

A small medicinal particle or grain made available
in its more stable dry form, to be reconstituted

With solvent just before dispensing to form a
suspension; the granules are so prepared to contain
not only the medicinal agent, but the colorants,
?avorants, and any other desired pharmaceutic

dosage form due to dif?culties in setting speci?c

DRUG DELIVERY

in its more stable dry form, to be reconstituted

A sterile preparation intended for parenteral use;

?ve distinct classes of injections exist as de?ned

or continuous phase), generally stabilized With one
or mom 6nullsifying agents- (Nomi Emulsion is

INJECTION,

by the USP_
An emulsion consisting of a sterile, pyrogen-free

used as a dosage form term unless a more speci?c

EMULSION

preparation intended to be administered

term is applicable, e. g. cream, lotion, ointment.)
A rectal preparation for therapeutic, diagnostic, or
nutritive purposes.

parenterally.
65 INJECTION, LIPID [de?nition pending]
COMPLEX
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TABLE 10-1 -continued

TABLE 10-1-c0ntinued

Dogge forms

Dogge forms

NAME

DEFINITION

NAME

DEFINITION

INJECTION,

A sterile preparation intended for reconstitution to

OINTMENT,

An ointment dosage form that enhances drug

POWDER,

form a solution for parenteral use.

AUGMENTED

delivery. Augmentation does not refer to the

FOR SOLUTION
INJECTION,
POWDER,
FOR SUSPENSION

INJECTION,
POWDER,

5

strength of the drug in the dosage form. NOTE:
CDER has decided to refrain from expanding the

A sterile preparation intended for reconstitution to
form a suspension for parenteral use.

use of this dosage form due to dil?culties in
setting speci?c criteria that must be met to be

10

A dried preparation intended for reconstitution to
form a suspension for parenteral use Which has

PASTE

FOR

considered “augmented”.
A semisolid3 dosage form, containing a large

proportion (20-50%) ofsolids ?nely dispersed in

SUSPENSION,
EXTENDED
RELEASE

been formulated in a manner to alloW at least a
reduction in dosing frequency as compared to that
drug presented as a conventional dosage form
(e.g., as a solution).

INJECTION,
POWDER,

A sterile freeze dried preparation intended for
reconstitution for parenteral use Which has been

15
PASTILLE

a fatty vehicle. This dosage form is generally for
external application to the skin or mucous
membranes.
An aromatic preparation, often With a pleasing

LYOPHILIZED,

formulated in a manner that Would alloW

flavor, usually intended to dissolve in the mouth.
A drug delivery system that often contains an
adhesive backing that is usually applied to an

FOR
LIPOSOMAL
SUSPENSION

liposomes (a lipid bilayer vesicle usually
composed of phospholipids Which is used to
encapsulate an active drug substance, either Within

passively diffuse from, or are actively transported
from, some portion of the patch. Depending upon

INJECTION,
SUSPENSION,
LIPOSOMAL

PATCH

external site on the body. Its ingredients either
20

a lipid bilayer or in an aqueous space) to be
formed upon reconstitution.

the patch, the ingredients are either delivered to
the outer surface of the body or into the body. A

A liquid preparation, suitable for injection, Which
consists of an oil phase dispersed throughout an
aqueous phase in such a manner that liposomes (a

patch is sometimes synonymous With the terms
‘extended release ?lm’ and ‘system’.
A drug delivery system in the form of a patch that

lipid bilay?r Vesicl? usually Composed of

PATCH,
25 EXTENDED

Phospholipids Which is used to 61103131113“? an
actIiW d-mg Substanc6> Fith?r Within a lipid bilay?r
or 1In

aqu?ous Ispac?) Iare fonn?Id'I

I

I

A liquid preparation, suitable for IHJECUOH, Which

SUSPENSION,

consists of solid particles dispersed throughout a

SONICATED

liquid phase in Which the particles are not soluble.
.

.

.

releases the drug in such a manner that a reduction

in dosing frequency compared to that drug
presented as a conventional dosage form (e.g., a
solution or a prompt drug-releasing, conventional

INJECTION,

. .

RELEASE

Solid dosag? form)_

PATCH,

A drug deliv?ry syst?m in th? form ofa patch

EXTENDED

Which is controlled by an electric current that

30

.

.

.

.

In addition, the product is sonicated While a gas is

JELLY

.

RELEASE,

th? formation ofmicrosph?ms by th? Solid

ELECTRICALLY

in dosing frequency compared to that drug

pmicl6S_
A class of gels, Which are semisolid systems that

CONTROLLED

presented as a conventional dosage form (e.g., a
Solution or a prompt drug'mleasing> conv?ntional

consist of suspensions made up of either small
inorganic pa?icles or large Organic molecules
interpenetrated by a liquidiin Which the structural
coherent matrix contains a high portion of liquid,

35
PELLET

usually Water.
KIT
LINIMENT

LIQUID’
EXTENDED
RELEASE

LOTION

An emulsion, liquidl dosage form. This dosage

LOTION,
AUGMENTED

Skin}
A lotion dosage form that enhances drug delivery.
Augmentation does not refer to the strength of the
drug in the dosage fOImI NOTE; CDER has

A solid dosage form in Which the drug itself is in
the form of granules to Which varying amounts of
coating have been applied, and Which releases a
drug (or drugs) in such a manner to alloW a
reduction in dosing frequency as compared to that
ding (or dings) pmsent?d as a conventional dosag?
form

45 PILL

A snlmln’ round slohd dosag? form contlallmng Ia

'

form is g?n?any for ?xt?mal application to th?

decided to refrain from expanding the use of this

50

or external use.

aqueous solution Which is most often used for

POWDER, FOR

An intimat? mixmm of dry, ?ndy divid?d dings

SOLUTION

and/or chemicals, Which, upon the addition of

its deodorant, refreshing, or antiseptic effect.

OINTMENT

.

An uncmous, Combustible Substanc? which is

60 POWDER, FOR
SUSPENSION

. .

Suitable v?hlclés’ ywlds a Solution‘ I I
An intimate mixture ofdry, ?nely divided drugs
and/or chemicals, Which, upon the addition of

preparation Containing the Solid Pmieles dispersal

<20% Water and volatiles5 and >50%

in the liquid vehicle).

hydrocarbons, Waxes, or polyols as the vehicle.
application to the skin or mucous membranes.

.

Suitable V?hicles, yi?lds a Susp?nsion (3 liquid

A semisolid3 dosage form, usually containing
This dosage form is generally for external

An intimat? mixmm ofdry, ?nd}, divid?d dings
and/or chemicals that may be intended for internal

,

liquid, or easily lique?able, on Warming, and is
Solubl? in ‘Ether but insolubl? in Watm Such
Substanws, dep?nding on than Origin, am
classi?ed as animal, mineral, or vegetable oils.

A soft, moist mass ofmeal, herbs, seed, etc.,
usually applied hot in cloth that consists of gmep

Mk6 consist?ncy
55 POWDER

:iflly m the mouth‘ A lollipop 1S a lounge on 5

OIL

Substance intended for external application made
of Such mammals and Ofsuch Consistency as to
ad-h?re to the Skin and attach to a dressing; Plast?rs
are intended to afford protection and support

With the skin.

POULTICE

medicaments, usually in a flavored, sWeetened
,

.

and/or to furnish an occlusion and macerating

criteria that must be met to be considered

,

.

action and to bring medication into close contact

“augm?nt?wA solid preparation containing one or more

base Which is intended to dissolve or disintegrate

.

medicinal agent intended for oral administration.
PLASTER

dosage form due to dif?culties in setting speci?c

MOUTHWASH

Solid dosag6 form)
A small sterile solid mass consisting ofa highly
puri?ed drug (With or Without excipients) made by
the formation of granules, or by compression and

PELLETS,
40 COATEDI
EXTENDED
RELEASE

conventional dosage form.

'

releases the drug in such a manner that a reduction

molding.

A Packag?d Collection Ofr?lat?d In?tefi?lA solution or mixture of various substances in oil,
alcoholic solutiops OIfSOaP, or emulsions intend?d
for I?xtfimal applIlcatlon'
I
A hquld that déhvérs a dfmg m Such a mann?r to
alloW a reduction in dosing frequency as
compared to that drug (or drugs) presented as a

LOZENGE

.

bubbled through th? susp?nsion, and this msults in

SALVE

65

A thick ointment or cerate (a fat or Wax based

preparation With a consistency betWeen an
ointment and a plaster).
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TABLE 10-1 -continued

TABLE 10-1-continued

Dogge forms

Dogge forms

NAME

DEFINITION

NAME

DEFINITION

SOLUTION

A clear, homogeneous liquidl dosage form that

TABLET,

A solid dosage form containing mixtures of acids

contains one or more chemical substances
dissolved in a solvent or mixture of mutually
miscible solvents.

EFFERVESCENT

(e. g., citric acid, tartaric acid) and sodium
bicarbonate, Which release carbon dioxide When
dissolved in Water; it is intended to be dissolved or

SOLUTION,
CONCENTRATE

SOLUTION, FOR
SLUSH

A liquid preparation (i.e., a substance that floWs
readily in its natural state) that contains a drug

5

10 TABLET,

dissolved in a suitable solvent or mixture of

EXTENDED

alloWs at least a reduction in dosing frequency as

mutually miscible solvents; the drug has been
strengthened by the evaporation of its nonactive
parts.

RELEASE

compared to that drug presented in conventional
dosage form.
A solid dosage form that contains medicinal

A solution for the preparation of an iced saline
slush, Which is administered by irrigation and used

TABLET, FILM
COATED

15

to induce regional hypothermia (in conditions

A solution that forms a gel When it comes in
contact With ocular fluid, and Which alloWs at least

EXTENDED

a reduction in dosing frequency.

RELEASE

A solution Which is usually administered in a

SOLUTION/

drop-Wise fashion.

substances With or Without suitable diluents and is
coated With a thin layer of a Water-insoluble or

Water-soluble polymer.

such as certain open heart and kidney surgical
procedures) by its direct application.
SOLUTION, GEL
A solution, Which after usually being administered
FORMING/DROPS in a drop-Wise fashion, forms a gel.
SOLUTION, GEL
FORMING,

dispersed in Water before administration.
A solid dosage form containing a drug Which

TABLET, FILM
COATED,
EXTENDED
RELEASE

A solid dosage form that contains medicinal
substances With or Without suitable diluents and is
coated With a thin layer of a Water-insoluble or
Water-soluble polymer; the tablet is formulated in
such manner as to make the contained medicament
available over an extended period of time

20

folloWing ingestion.
TABLET, FOR

A tablet that forms a solution When placed in a

SOLUTION

liquid.

TABLET, FOR

A tablet that forms a suspension When placed in a

SUSPENSION

liquid (formerly referred to as a ‘dispersible
tablet’).

the human body; they usually melt, soften, or

TABLET,

A solid dosage form containing medicinal

MULTILAYER

SUPPOSITORY,
EXTENDED

dissolve at body temperature.
A drug delivery system in the form of a
suppository that alloWs for a reduction in dosing

substances that have been compressed to form a
multiple-layered tablet or a tablet-Within-a-tablet,
the inner tablet being the core and the outer

RELEASE
SUSPENSION

frequency.
A liquid1 dosage form that contains solid particles
dispersed in a liquid vehicle.

MULTILAYER,

substances that have been compressed to form a

SUSPENSION,

A liquid preparation consisting of solid particles

EXTENDED

multiple-layered tablet or a tablet-Within-a-tablet,

EXTENDED

dispersed throughout a liquid phase in Which the

RELEASE

the inner tablet being the core and the outer

RELEASE

particles are not soluble; the suspension has been

DROPS

SUPPOSITORY

A solid body of various Weights and shapes,
adapted for introduction into the rectal ori?ce of

formulated in a manner to alloW at least a
reduction in dosing frequency as compared to that

25

30 TABLET,

portion being the shell.
A solid dosage form containing medicinal

portion being the shell, Which, additionally, is
covered in a designated coating; the tablet is
formulated in such manner as to alloW at least a

35

drug presented as a conventional dosage form

reduction in dosing frequency as compared to that

(e.g., as a solution or a prompt drug-releasing,

drug presented as a conventional dosage form.

conventional solid dosage form).
A suspension Which is usually administered in a

TABLET,
ORALLY

DROPS

dropWise fashion.

DISINTEGRATING Within a matter of seconds, When placed upon the

SYRUP

An oral solution containing high concentrations of

SUSPENSION/

sucrose or other sugars; the term has also been

A solid dosage form containing medicinal
substances Which disintegrates rapidly, usually
tongue.

40 TABLET,

A solid dosage form containing medicinal

used to include any other liquid dosage form

ORALLY

substances Which disintegrates rapidly, usually

TABLET

prepared in a sWeet and viscid vehicle, including
oral suspensions.
A solid dosage form containing medicinal

DISINTEGRATING,
DELAYED

Within a matter of seconds, When placed upon the
tongue, but Which releases a drug (or drugs) at a
time other than promptly after administration.

TABLET,

A solid dosage form containing medicinal

CHEWABLE

substances With or Without suitable diluents that is

substances With or Without suitable diluents.

RELEASE

45 TABLET,

intended to be cheWed, producing a pleasant
tasting residue in the oral cavity that is easily
sWalloWed and does not leave a bitter or
unpleasant after-taste.

TABLET,

A solid dosage form that contains medicinal

COATED

substances With or Without suitable diluents and is

TABLET,
COATED

covered With a designated coating.
A Solid dosage fon'n containing a conglomerate of
medicinal particles that have each been covered

PARTICLES
TABLET,
DELAYED

Wlth a coatlngA SOlid dosage form Which releases a drug (or
drugs) at a tim? other than promptly a?er

RELEASE

.

substances With or Without suitable diluents and

TABLET, SUGAR

possesses the ability to dissolve in fluids.
A solid dosage form that contains medicinal

COATED

50

A solid dosage form that contains medicinal

SOLUBLE

substances With or Without suitable diluents and is
coated With a colored or an uncolored Water

soluble sugar.
Footnotes:
1A liquid is pourable; it ?oyvs and conforms to its container at room temperature. It displays
glewtf‘mn or pseudqlllasm ?ow. behavnlr'
.
.

.

Previously the de?nition ofa lotion Was The term lotion has been used to categorize many

55

topical suspensions, solutions, and emulsions intended for application to the skin.” The
gurrentde?iniition ofa lotion ‘is restricted to an emulsion. I
I
A semisolid is notpourable; it does not How or conform _to its container atroom temperature.

administration- Enmrimcoamd micl?s an? dday?d

‘ItAdoes
not ?oW at loW shear stress ‘and generally exhibits plastic ?oW behavior.
I
colloidal dispersion is a system in Which particles ofcolloidal dimension (i.e., typically

T616356 dosage forms-

betWeen 1 nm and 1 pm) are distributed uniformly throughout a liquid.

TABLET,

A solid dosage fon'n containing a conglomerate of

5Percent Water and volatiles are measured by_ a loss on drying test in Which the sample is

DELAYED

medicinal particles that have been covered With a

heated at 1050 C‘ untll Constant Welght 1S achleved'

RELEASE
PARTICLES

coating Which releases a drug (or drugs) at a time
other than promptly after administration. Entericcoated articles are delayed release dosage forms.

TABLET,

A tablet that, prior to administration, is intended to

DISPERSIBLE

be placed in liquid, Where its contents Will be

dlsmbut?‘l evenly glroughouf?mt liquid‘ Note:
The term tablet, dispersible is no longer used for

approved drug products, and it has been replaced
by the term ‘tablet, for suspension’.

60

EXAMPLE 1 1

Route of administration. A suitable route of administration
_

_

_

_

65 for a dosage form containing a pharmaceutically active com

pound of the present invention may be chosen from among
those listed in Table 11-1.

US 8,426,368 B2
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TABLE 11-1

TABLE 1 1-1 -continued

Routes of administration

Routes of administration

NAME

DEFINITION

BUCCAL

Administration directed toWard the cheek,
generally from Within the mouth.
Administration to the conjunctiva, the
delicate membrane that lines the eyelids

CONIUNCTIVAL

CUTANEOUS
ENDOSINUSIAL

ENTERAL
EPIDURAL

5

and covers the exposed surface of the
eyeball.
Administration to the skin.
Administration Within the nasal sinuses of
the head.
Administration directly into the intestines.
Administration upon or over the dura
mater.

NAME

DEFINITION

INTRAVITREAL

Administration Within the vitreous body of
the eye.
Administration to the nose; administered
by Way of the nose.

NASAL
OPHTHALMIC
10 ORAL
OROPHARYNGEAL

Administration to the external eye.
Administration to or by Way of the mouth.
Administration directly to the mouth and
pharynx.
Administration is different from others on
this list.
Administration by injection, infusion, or
implantation.

OTHER

PARENTERAL

15

EXTRACORPOREAL
HEMODIALYSIS

Administration outside of the body.
Administration through hemodialysate

PERCUTANEOUS
PERIARTICULAR

Administration through the skin.
Administration around a joint.

fluid.
Administration that results in substances

PERIDURAL

INFILTRATION

passing into tissue spaces or into cells.

PERINEURAL

Administration to the outside of the dura
mater of the spinal cord..
Administration surrounding a nerve or

INTERSTITIAL

Administration to or in the interstices of a

INTRA-ABDOMINAL
INTRA-ARTERIAL

tissue.
Administration Within the abdomen.
Administration Within an artery or arteries.

INTRA-ARTICULAR
INTRACARTILAGINOUS
INTRACAUDAL
INTRACORONARY
INTRADERMAL
INTRADUCTAL
INTRADUODENAL
INTRADURAL
INTRAEPIDERMAL
INTRAESOPHAGEAL
INTRAGASTRIC
INTRAGINGIVAL

nerves.

20 PERIODONTAL
RECTAL
RESPIRATORY

Administration around a tooth.
Administration to the rectum.
Administration Within the respiratory tract

Administration Within a joint.
Administration Within a cartilage;
endochondral.
Administration Within the cauda equina.
Administration Within the coronary
arteries.
Administration Within the dermis.
Administration Within the duct of a gland.

(INHALATION)

25 SUBCONIUNCTIVAL
SUBCUTANEOUS

Administration Within the duodenum.
Administration Within or beneath the dura.
Administration Within the epidermis.

30

by inhaling orally or nasally for local or
systemic effect.
Administration into any soft tissue.
Administration beneath the conjunctiva.
Administration beneath the skin;
hypodermic. Synonymous With the term
SUBDERMAL.
Administration beneath the tongue.

SOFT TISSUE

SUBLINGUAL
SUBMUCOSAL

Administration beneath the mucous
membrane.
Administration to a particular spot on the

TOPICAL

Administration Within the esophagus.

outer surface of the body. The EZB term

Administration Within the stomach.

TRANSMAMMARY is a subset of the

Administration Within the gingivae.

INTRALYMPHATIC
INTRAMEDULLARY

Administration Within the lymph.
Administration Within the marroW cavity

INTRAMENINGEAL

ofa bone.
Administration Within the meninges (the

term TOPICAL.

TRANSDERMAL

Administration through the dermal layer
of the skin to the systemic circulation by

35

diffusion.
Administration across the mucosa.

TRANSMUCOSAL

three membranes that envelope the brain

INTRAMUSCULAR

and spinal cord).
Administration Within a muscle.

INTRAOCULAR

Admlnlstmtlon Wlthln the W6‘

The foregoing description of the preferred embodiments of

40 the present invention have been presented for purposes of

INTRAOVARIAN

Adm1n1strat1on Within the ovary.

.

INTRAPERICARDIAL
INTRAPERITONEAL

Administration Within the pericardiwn
Administration Within the peritoneal

1llustrat1on and descnptlon. It 15 not 1ntended to be exhaustlve
or to limit the invention to the precise form disclosed. Obvi

CavltY- I

I

I

I

INTRAPLEURAL

Adm1n1strat1on Within the pleura.

INTRAPULMONARY

Administration Within the lungs or its

INTRASINAL

Admlmsmltlon Wlthm the nasal or

bronchi.

.

.

.

.

.

.

ous modi?cations or variations are possible in light of the
.

.

above teachlngs' The embodlments Were Chosen and

45 described to provide the best illustration of the principles of
the invention and its practical application to thereby enable

periorbital sinuses.

.

.

.

.

.

.

.

.

INTRASPINAL

Administration Within th? vembml
column

INTRASYNOVIAL
INTRATENDINOUS

Agimliliistmtion Within L116 synovial Cavity
Administration Within a m1don

INTRATHECAL

Administration Within the cerebrospinal
fluid at any level of the cerebrospinal axis,
including ini?ction into th? Cmbml

determlned by the appended cla1ms When Interpreted 1n
accordance With the breadth to Which they are fairly, legally

V?nmcl?s'
Administration Within the thorax (internal
to the ribs); Synonymous with the mm
endothoracic.

ments do not and are not intended to limit the ordinary mean
,
,
,
,
,
,
,
,
mg of the cla1ms 1n the1r fan and broad 1nterpretat1on 1n any
Way

INTRATHORACIC

INTRATUMOR

O

a JOmtI

50

suited to the particular use contemplated. All such modi?ca
t1ons and var1at1ons are W1th1n thescope of the 1nvent1on as
.

.

.

.

.

.

.

and equitably entitled. The draWings and preferred embodi
55

Administration Within a tumor.

INTRAUTERINE

Administration Within the uterus.

INTRAVASCULAR

Adm1n1strat1on Within a vessel or vessels.

INTRAVENOUS

Administration Within or into a vein or
veins.
Administration Within or into a vein or
v?ins all at 01m-

INTRAVENOUS BOLUS

one of ordmary sk1ll 1n the art to ut1l1Ze the 1nvent1on 1n
various embodiments and With various modi?cations as are

INTRAVENOUS DRIP

Administration Within or into a vein or

INTRAVENTRICULAR
INTRAVE S ICAL

veins over a sustained period of time.
Administration Within a ventricle.
Administration Within the bladder.

\Vhat is ClailnedZ
.

60
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.

_1: A method of supplemennng a dlet of a mammal’ Com
PI‘lSlIlgZ
administering to said mammal a pharmaceutically effec
tive amount of a compound having a chemical formula:
R1
R2 / \ R2

US 8,426,368 B2
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Where R1:

Where R2:

0
5

—C—NH—(CH2)n—SR4 or —C—NH—C—CH2—SR4;

\

('3
R3

N

/

,

10

and

or

Where R2:

15

O
O
_C_NH_(CHZ)K_SR4 or _C_NH_C_CH2_SR4

2-mercaptoethanol, dithiothreitol, iodoacetate, bro
moacetate, ?uoroacetate or chloroacetate and n:2-4.

(I)
R3
3

20

4

WheFe R iethyl .Or methyl’

and
Where R3 :ethyl or methyl, R4Ihydro gen, glutathione, cys
teine, alphadihydrolipoic acid, cystamine, thiolphos
phate, 5'thioladenosine, L-homocysteine, co-enZyme A,

_

11. The method of claim 10, including using oral admin
istration.

ihydrogen’ glutathlqne’ cys_

12. The method of claim 10, including administering

te1ne, alphad1hydrol1po1c ac1d, cystam1ne, thiolphos, -

. .
.
betWeen about 0.5 and about 40 milligrams of sa1d compound

phate, 5 th1oladenos1ne, L-homocysteme, co-enZyme A,

k1

f

,d

1,

1b d

2-mercaptoethanol, dithiothreitol, iodoacetate, bro- 25 per 1 Ogram O Sal mamma 5 tom

_ h

d

0 y Welg tper ay'

moacetate, ?uoroacetate or chloroacetate and n:2-4.
13. The method of claim 10, including using transderrnal
2. The method of claim 1, including using oral administraadmlmstranon'
tion.
14. The method of claim 10, including using nasal admin
3. The method of claim 1, including administering betWeen 30 istration
about 0-5 and about 40 milligrams Of Said Compound Per
15. The method of claim 10, including using administra

kilogram of said mammal’s total body Weight per day.
4~_ The method of Claim 1, including using transdermal

tion by Suppository.
16. The method of claim 10, including using intravenous

adm1n1strat1on.

administration

5} The method of Claim 1’ including using nasal adminis' 35
tranon'

_

_

_

_

_

_

_

b 6' The ?ethod of Clalm 1’ lncludmg usmg admlmstranon
y supposl Ory'

_

_

_

_

17. The method of claim 10, including administering said
compound With a Water soluble metal chelator.

18. The method of claim 17, including selecting said Water

_

soluble metal chelator from a group consisting of glutathione

7-_ The method Of 01mm 1, lncludlng 115mg Intravenous 40 (GSH), dihydrolipoic acid (DLPA), lipoic acid (LPA),N-ace
admlmstranon'
tylcysteine (NAC), dimercaptopropane sultanate (DMPS),
8. The method of claim 1, including administering said

dimercaptosuccinic acid (DMSA), ethylenediaminetetraace

compound With another antiOXidanItie acid (EDTA) and mixtures thereof.
9. The method of claim 1. including selecting said antioxi19_ A method Of relieving Oxidative Stress in a mammal,
dant from a list of antioxidants consisting of Vitamin-E, Vita- 45 Comprising.
min-D, cysteine, glutathione, lipoic acid and combinations

_ _

thereof

_

_

_

adm1n1stering to sa1d mammal a pharmaceutically effec

10' A method to remove heavy metals and toxins from a

t1Ve amount of a compound having a chemical formula:

mammal, comprising:
administering to said mammal a pharmaceutically effec- 50

l

tiVe amount of a compound having a chemical formula:

R2/R\ R2

1

R2/R\ R2
55

Where R1:

Where R1:

60

\
N/

\
,

65

/

N

,
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Where R2:

Where R2:
O

O

0
0
0

and
10

Where R3Iethyl or methyl, R4 hydrogen, glutathione, cys

teine, alphadihydrolipoie acid, cystamine, thiolphos

and

phate, 5'thioladenosine, L-homocysteine, co-enZyme A,
2-mercaptoethanol, dithiothreitol, iodoacetate, bro

Where R3 :ethyl or methyl, R4:hydrogen, glutathione, cys

teine, alphadihydrolipoic acid, cystamine, thiolphos

moacetate, ?uoroacetate or chloroacetate and n:2-4;
and

phate, 5'thioladenosine, L-homocysteine, co-enZyme A,
2-mercaptoethanol, dithiothreitol, iodoacetate, bro

a pharmaceutically acceptable excipient.

moacetate, ?uoroacetate or chloroacetate and n:2-4.

31. The composition of claim 30, Wherein said excipient is

20. The method of claim 19, including using oral admin

selected from a group of materials consisting of Acacia,

istration.

Acesulfame Potassium, Acetic Acid, Acetone, Acetyltributyl

21. The method of claim 19, including administering
betWeen about 0.5 and about 100 milligrams of said com

20

pound per kilogram of said mammal’s total body Weight per

day.
22. The method of claim 19, including using transderrnal

Citrate, Acetyltr‘iethyl Citrate, Agar, Albumin, Alcohol, Alg
inic Acid, Aliphatic Polyesters, Alitame, Almond Oil, Alpha
Tocopherol, Aluminum Hydroxide Adjuvant, Aluminum
Oxide, Aluminum Phosphate Adjuvant, Aluminum Stearate,
Ammonia Solution, Ammonium Alginate, Ascorbic Acid,

administration.

Ascorbyl Palmitate, Aspartame, Attapulgite, Bentonite, Ben

23. The method of claim 19, including using nasal admin

25

istration.

Zalkonium Chloride, BenZethonium Chloride, BenZoic Acid,

BenZyl Alcohol, BenZyl BenZoate, Bor‘ic Acid, Bronopol,

Butylated Hydroxyanisole, Butylated Hydroxytoluene,

24. The method of claim 19, including using administra

tion by suppository.
25. The method of claim 19, including using intravenous
30

administration.

26. The method of claim 19, including administering said
compound With a precursor of glutathione,
27. The method of claim 26, including selecting said pre
cursor of glutathione from a group consisting of cysteinc,

N-acetylcysteine, glycine, glutamate and combinations

Dioxide, Carboxymethylcellulose Calcium, Carboxymethyl
35

thereof.

28. The method of claim 19, including administering said
compound With a dietary supplement that supports glu
tathione synthesis.
29. The method of claim 28, including selecting said
dietary supplement from a group consisting of Whey protein,
N-acetylcysteine, cysteine, glutathione, nicotine adenine

40

(NADH), glycylcysteine (gly-cys), glutamylcysteine (glu
45

30. A pharmaceutical composition, comprising:

Chlorodi?uoroethane (HCFC), Chloro?uorocarbons (CFC),
Chloroxylenol, Cholesterol, Citric Acid Monohydrate, Col
loidal, Silicon Dioxide, Coloring Agents, Copovidone, Com
Oil, Cottonseed Oil, Cresol, Croscar'mellose Sodium,

Crospovidone, Cyclodextr‘ins, Cyclomethicone, Denatonium
BenZoate, Dextrates, Dextrin, Dextrose, Dibutyl Phthalate,
Dibutyl Sebacate, Diethanolamine, Diethyl Phthalate, Dif
luoroethane (HFC), Dimethicone, Dimethyl Ether, Dimethyl
Phthalate, Dimethyl Sulfoxide, Dimethylacetamide, Diso
dium Edetate, Docusate Sodium, Edetic Acid, Erythorbic

a pharmaceutically effective amount of a compound hav
ing a chemical formula:
50

Where R1:

cellulose Sodium, Carrageenan, Castor Oil, Hydrogenated
Castor Oil, Cellulose, Microcrystalline, Cellulose, PoW
dered, Cellulose, Silici?ed Microcrystalline, Cellulose
Acetate, Cellulose Acetate Phthalate, Ceratonia, Cetostearyl
Alcohol, Cetrimide, Cetyl Alcohol, Cetylpyridinium Chlo

ride, Chitosan, Chlorhexidine, Chlorobutanol, Chlorocresol,

dinucleotide (NAD+), reduced nicotine adenine dinucleotide

cys), and combinations thereof.

Butylparaben, Calcium Alginate, Calcium Carbonate, Cal
cium Phosphate, Dibasic Anhydrous, Calcium Phosphate,
Dibasic Dihydrate, Calcium Phosphate, Tribasic, Calcium
Stearate, Calcium Sulfate, Canola Oil, Carbomer, Carbon

55

60

/
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Acid, Erythritol, Ethyl Acetate, Ethyl Lactate, Ethyl Maltol,
Ethyl Oleate, Ethyl Vanillin, Ethylcellulose, Ethylene Glycol
Palmitostearate, Ethylene Vinyl Acetate, Ethylparaben, Fruc
tose, Fumar‘ic Acid, Gelatin, Glucose, Glycerin, Glyceryl
Behenate, Glyceryl Monooleate, Glyceryl Monostearate,
Glyceryl Palmitostearate, Glycofurol, Guar Gum, Hector‘ite,
Hepta?uoropropane (HFC), Hexetidine, Hydrocarbons
(HC), Hydrochlor‘icAcid, Hydroxyethyl Cellulose, Hydroxy
ethylmethyl Cellulose, Hydroxypropyl Cellulose, Hydrox
ypropyl Cellulose, LoW-substituted, Hydroxypropyl Starch,
Hypromellose, Hypromellose Acetate Succinate, Hypromel
lose Phthalate, lmidurea, lnulin, Iron Oxides, lsopropylAlco
hol, lsopropyl Myr‘istate, lsopropyl Palmitate, Kaolin, Lactic
Acid, Lactitol, Lactose Anhydrous, Lactose Monohydrate,
Lactose Spray-Dried, Lanolin, Lanolin Hydrous, Lanolin
Alcohols, Lauric Acid, Lecithin, Leucine, Linoleic Acid,
Macrogol l5 Hydroxystearate, Magnesium Aluminum Sili

cate, Magnesium Carbonate, Magnesium Oxide, Magnesium
Silicate, Magnesium Stearate, Magnesium Trisilicate, Malic
Acid, Maltitol, Maltitol Solution, Maltodextr‘in, Maltol, Mal
tose, Mannitol, Mediumchain Triglycerides, Meglumine,

